CTF1 and obesity disorder: Although promising protective activities have been shown for CT-1 against liver apoptosis [15], hepatocyte ischemic injury [16], and renal toxicity of iodinated contrast media [17], evidence from basic research studies indicates CT-1 to be a controversial molecule with potential opposite activities in obesity, insulin resistance, and related increased cardiovascular risk.